Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Coloplast A/S    COLO B   DK0060448595


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coloplast A/S : delivers solid Q1 interim results and continues to take market share

02/01/2018 | 07:20am EST

Coloplast delivered 8% organic revenue growth in the first three months of the 2017/18 financial year, while reported growth in Danish kroner was up by 5% to DKK 3,955m. Reported revenue was adversely affected by the depreciation of USD and dollar-related currencies against DKK.

EBIT amounted to DKK 1,207m for a 2% decline in DKK but a 4% increase at constant exchange rates. The EBIT margin at constant exchange rates was 31% against 33% in the same period last year. In DKK, the EBIT margin was 31%, against 33% last year.

Organic growth rates by business area: Ostomy Care 9%, Continence Care 10%, Urology Care 11%, and Wound & Skin Care negative at 5%. Organic growth, particularly in the wound care business, was adversely affected by price reforms in Greece.

Looking at sales by geographies, the European markets contributed with 4% growth, Other developed markets delivered 18% revenue growth, while Emerging Markets provided a 10% increase.

'We're delivering a solid result for the first quarter, and we are off to a good start to the financial year. We're performing well in many of our major markets and are generally delivering strong results in Ostomy Care, Continence Care and Urology Care. As an example, we're delivering double-digit growth, and we see continued increased momentum in the US market,' says Coloplast CEO Lars Rasmussen.

Coloplast invests in growth
Coloplast invested in sales and marketing initiatives across multiple markets and business areas during the first quarter as part of its ambition to drive organic growth.

In addition, Coloplast is adding a new product to its ostomy care portfolio with the launch of SenSura® Mio Concave, the first ostomy care product designed specifically for people with hernias or curves.

'We're proud to be able to offer our users the best products in the market, and I'm confident that this new product will make a big difference to our users while giving Coloplast a strong competitive edge. Our ambition is to continue to win market share, and to do that we need innovative products like SenSura® Mio Concave,' says Mr Rasmussen.

In November 2017, Coloplast presented its new long-term financial guidance for the period to 2020. Consistent with its ambition of pursuing non-organic growth opportunities, Coloplast completed the acquisition of French direct-to-consumer home delivery company SAS Lilial in January 2018.

The transaction will strengthen Coloplast's position and its product and service offering in France and will open for further access to payers.

Financial guidance for 2017/18
Coloplast continues to expect organic revenue growth of ~7% at constant exchange rates. Guidance for reported growth in DKK is lowered by 1pp to 5%-6% due to developments in the USD/DKK exchange rate. The guidance includes a negative effect of DKK 100m due to the patent expiry of SpeediCath® standard catheters and the effects of a comprehensive healthcare reform in Greece of DKK 100m.

Coloplast continues to expect an EBIT margin of 31%-32% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

Lina Danstrup

Senior Media Relations Manager, Corporate Communications

+45 49 11 26 07


Ellen Bjurgert

Director, Investor Relations

+45 49 11 33 76


Coloplast A/S published this content on 01 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 01 February 2018 12:19:11 UTC.

Publicnow 2018
All news about COLOPLAST A/S
06:00aCOLOPLAST A/S : - Transactions in connection with share buy-back programme, wee..
02/19COLOPLAST A/S : - Announcement no. 02/2021 - Share Buyback Programme
02/15COLOPLAST A/S : - Trading in Coloplast shares by board members, executives or a..
02/02Global equities rally as more U.S. stimulus looms, silver slides
02/02Global equities rally as more U.S. stimulus looms, silver slumps
02/02EUROPE : European shares rise on recovery hopes, LVMH leads
02/02COLOPLAST A/S : Shares Jump As Fiscal Q1 Profit Rises On Organic Growth, Solid ..
02/02COLOPLAST A/S : delivers a good start to the year with 5% organic growth in Q1 ..
02/02COLOPLAST A/S : - Announcement no. 01/2021 – Interim Financial Report, Q1..
02/02COLOPLAST A/S : 1st quarter results
More news
Sales 2021 19 498 M 3 159 M 3 159 M
Net income 2021 4 755 M 771 M 771 M
Net Debt 2021 1 712 M 277 M 277 M
P/E ratio 2021 42,4x
Yield 2021 2,02%
Capitalization 202 B 32 714 M 32 697 M
EV / Sales 2021 10,4x
EV / Sales 2022 9,65x
Nbr of Employees 12 500
Free-Float 57,3%
Duration : Period :
Coloplast A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 19
Average target price 965,67 DKK
Last Close Price 947,60 DKK
Spread / Highest target 21,4%
Spread / Average Target 1,91%
Spread / Lowest Target -15,6%
EPS Revisions
Managers and Directors
Kristian Villumsen President & Chief Executive Officer
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Lars Sren Rasmussen Chairman
Oliver Johansen Senior VP-Global Research & Development
Allan Rasmussen Executive Vice President-Global Operations
Sector and Competitors